Cardiopulmonary effects of romifidine/ketamine or xylazine/ketamine when used for short duration anesthesia in the horse.
The cardiovascular changes associated with anesthesia induced and maintained with romifidine/ketamine versus xylazine/ ketamine were compared using 6 horses in a cross over design. Anesthesia was induced and maintained with romifidine (100 microg/kg, IV)/ketamine (2.0 mg/kg, IV) and ketamine (0.1 mg/kg/min, IV), respectively, in horses assigned to the romifidine/ ketamine group. Horses assigned to the xylazine/ketamine group had anesthesia induced and maintained with xylazine (1.0 mg/kg, IV)/ketamine (2.0 mg/kg, IV) and a combination of xylazine (0.05 mg/kg/min, IV) and ketamine (0.1 mg/kg/min, IV), respectively. Cardiopulmonary variables were measured at intervals up to 40 min after induction. All horses showed effective sedation following intravenous romifidine or xylazine and achieved recumbency after ketamine administration. There were no significant differences between groups in heart rate, arterial oxygen partial pressures, arterial carbon dioxide partial pressures, cardiac index, stroke index, oxygen delivery, oxygen utilization, systemic vascular resistance, left ventricular work, or any of the measured systemic arterial blood pressures. Cardiac index and left ventricular work fell significantly from baseline while systemic vascular resistance increased from baseline in both groups. The oxygen utilization ratio was higher in the xylazine group at 5 and 15 min after induction. In conclusion, the combination of romifidine/ketamine results in similar cardiopulmonary alterations as a xylazine/ketamine regime, and is a suitable alternative for clinical anesthesia of the horse from a cardiopulmonary viewpoint.
Kerr
Carolyn L
CL
Department of Clinical Studies, University of Guelph, Guelph, Ontario N1G 2W1. ckerr@uoguelph.ca
McDonell
Wayne N
WN
Young
Simon S
SS
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology*; D000758:Anesthesia / Q000379:methods / Q000662:veterinary*; D019162:Anesthetics, Combined / Q000494:pharmacology*; D000778:Anesthetics, Dissociative / Q000494:pharmacology*; D000818:Animals; D001784:Blood Gas Analysis; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D018592:Cross-Over Studies; D006339:Heart Rate / Q000187:drug effects; D006736:Horses / Q000097:blood / Q000502:physiology*; D007093:Imidazoles / Q000494:pharmacology*; D007649:Ketamine / Q000494:pharmacology*; D010101:Oxygen Consumption; D010313:Partial Pressure; D011897:Random Allocation; D012119:Respiration / Q000187:drug effects; D014991:Xylazine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D019162:Anesthetics, Combined; D000778:Anesthetics, Dissociative; D007093:Imidazoles; D002245:Carbon Dioxide; D014991:Xylazine; D007649:Ketamine; C076257:romifidine